← All trials
NCT04005755
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2019
- Primary completion
- Oct 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 225
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AFT Pharmaceuticals, Ltd.Lead sponsor
- Chesapeake Research Group, LLCOverall official - principal investigator
- Southern Clinical Trials LtdOverall official - principal investigator
- Chapel Hill Research GroupOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.